Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches.

ABSTRACT: Immunotherapy is extensively investigated for almost all types of hematologic tumors, from preleukemic to relapse/refractory malignancies. Due to the emergence of technologies for target cell characterization, antibody design and manufacturing, as well as genome editing, immunotherapies including gene and cell therapies are becoming increasingly elaborate and diversified. Understanding the tumor immune microenvironment of the target disease is critical, as is reducing toxicity. Although there have been many successes and newly FDA-approved immunotherapies for hematologic malignancies, we have learned that insufficient efficacy due to disease relapse following treatment is one of the key obstacles for developing successful therapeutic regimens. Thus, combination therapies are also being exp

SUBMITTER: Noh JY 

PROVIDER: S-EPMC7663624 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature